Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.72 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.72 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.72 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL999074 | 1.00 | ADORA3 (0.72) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL3946675 | 0.87 | ADORA2A (0.72) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL5397531 | 0.87 | ADORA2A (0.72) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL5033794 | 0.83 | ADORA2A (0.76) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL3952630 | 0.83 | ADORA2A (0.76) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL5393611 | 0.82 | ADORA3 (0.92) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL4806342 | 0.82 | ADORA3 (0.76) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL3956133 | 0.82 | ADORA3 (0.92) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL5034108 | 0.82 | ADORA3 (0.70) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL5034419 | 0.82 | ADORA3 (0.70) | ADORA3ADORA2AADORA1ADORA2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293720-B2 | Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists | DOGWOOD PHARMACEUTICALS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8263762-B2 | Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as A2AR agonists | DOGWOOD PHARMACEUTICALS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8252767-B2 | Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists | DOGWOOD PHARMACEUTICALS, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| EP-2448953-A1 | ALKOXY-CARBONYL-AMINO-ALKYNYL-ADENOSINE COMPOUNDS AND DERIVATIVES THATREOF AS A2AR AGONISTS | Forest Laboratories Holdings Limited (BM) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002917-A1 | ALKOXY-CARBONYL-AMINO-ALKYNYL-ADENOSINE COMPOUNDS AND DERIVATIVES THEREOF AS A2A R AGONISTS | PGXHEALTH, LLC (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20110003766-A1 | ALKOXY-CARBONYL-AMINO-ALKYNYL-ADENOSINE COMPOUNDS AND DERIVATIVES THEREOF AS A2AR AGONISTS | ADENOSINE THERAPEUTICS, LLC | 2011-01-06 | — | — | US | disclosed |
| US-20110003765-A1 | SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS | ADENOSINE THERAPEUTICS, LLC | 2011-01-06 | — | — | US | disclosed |
| CN-101938906-A | Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydrofuran-2-yl)-9H-purin-2-yl]-propan-2-ynyl}-piperidine-1-carboxylic acid ester as A2AR agonist | PGXHEALTH LLC | 2011-01-05 | — | — | CN | disclosed |
| US-20090162292-A1 | SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS | PGXHEALTH, LLC (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003765-A1 | SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA2A 1/4885ADORA1 3/4885 |
| US-20090162292-A1 | SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA2A 1/4885ADORA1 3/4885 |
| US-20110003766-A1 | ALKOXY-CARBONYL-AMINO-ALKYNYL-ADENOSINE COMPOUNDS AND DERIVATIVES THEREOF AS A2AR AGONISTS | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA2A 1/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.